Latest Cardium Therapeutics Inc. Comm (CRXM) Headl
Post# of 72
Posted On: 03/09/2014 12:05:01 PM
Latest Cardium Therapeutics Inc. Comm (CRXM) Headlines
Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development Of Advanced Regenerative Therapeutics
PR Newswire - Mon Mar 03, 8:00AM CST
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.
Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
PR Newswire - Mon Jan 27, 8:00AM CST
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx® Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen® for wound healing and as a biologics delivery platform.
Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development Of Advanced Regenerative Therapeutics
PR Newswire - Mon Mar 03, 8:00AM CST
Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.
Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings
PR Newswire - Mon Jan 27, 8:00AM CST
Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx® Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen® for wound healing and as a biologics delivery platform.
(0)
(0)Cardium Therapeutics Inc (CRXM) Stock Research Links
Scroll down for more posts ▼